SCHEMBL2471969

SCHEMBL2471969

COc1ccccc1C(=O)NC(C1(c2ccccc2)CCNCC1)S(=O)(=O)Nc1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.40
ITGA4 P13612 1/20 0.38
ITGB7 P26010 1/20 0.38
KCNA3 P22001 5/20 0.38
JAK2 O60674 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
SLC6A9 P48067 1/20 0.37
CASP3 P42574 1/20 0.37
TSHR P16473 2/20 0.36
NAMPT P43490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469444 0.94 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AHPGDKCNA3
SCHEMBL2469955 0.91 ITGA4 (0.43) POLBALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL2472448 0.90 GAA (0.41) POLBALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL2468788 0.88 RAB9A (0.48) POLBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL2471838 0.87 POLB (0.49) POLBALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL2471043 0.86 POLB (0.41) POLBALDH1A1MEN1KMT2AHPGD
SCHEMBL2469730 0.86 ALDH1A1 (0.45) ALDH1A1MEN1KMT2AHPGDITGA4
SCHEMBL2467857 0.86 ALDH1A1 (0.45) ALDH1A1MEN1KMT2AHPGDITGA4
SCHEMBL2471492 0.85 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL2701253 0.85 CASP3 (0.39) POLBALDH1A1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 POLB 4413/4885ALDH1A1 3941/4885MAPT 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.